GLN 1062

Drug Profile

GLN 1062

Alternative Names: Galantamine pro-drug - Galantos Pharma; GLN-1062; Memogain; Pro-galantamine - Galantos Pharma

Latest Information Update: 22 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galantos Pharma
  • Developer Galantos Pharma; Neurodyn
  • Class Alkaloids; Benzazepines; Nootropics; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 19 Dec 2017 Neurodyn plans a phase II development program for GLN-1062
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in Canada (Intranasal, Spray)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top